Skip to main content

Table 1 Patients and tumour characteristics

From: Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors

Variable Number of patients (%)
Number of the patients
Grade
53 (aged 40–94, mean 67)
   I 7 (13.2%)
   II 24 (45.3%)
   III 18 (34%)
   in situ II 1 (1.9%)
   in situ III 3 (5.7%)
Axillary nodal status  
   N0 25 (47.2%)
   N1–3 12 (22.6%)
   N4–9 11 (20.8%)
   >N10 3 (5.7%)
   Unknown (axillary evacuation done 1993 and 1994) 2 (3.8%)
Tumour size  
   ≤ 2 cm 13 (24.5%)
   > 2 cm 40 (75.5%)
Estrogen receptor status (ER) 1)  
   Positive 35 (66%)
   Negative 14 (26.4%)
   Positive in DCI 3 (5.7%)
   Negative in DCIS 1 (1.9%)
Progesterone receptor status (PR) 1)  
   Positive 36 (68%)
   Negative 13 (24.5%)
   Positive in DCIS 3 (5.7%)
   Negative in DCIS 1 (1.9%)
Ki-67 status  
   <5% 7 (13.2%)
   5–19% 16 (30.2%)
   20–29% 8 (15.1%)
   >20% 22 (41.5%)
Histologic type  
   Ductal 37 (69.8%)
   Lobular 8 (15.1%)
   Subtypes 4 (7.5%)
   Ductal carcinoma in situ 4 (7.5%)
Her-2 2)  
   IHC positive (2+ and 3+) 20 (37.7%)
   IHC negative (0 and 1+) 29 (54.7%)
   IHC positive in DCIS 2 (3.8%)
   IHC negative in DCIS 2 (3.8%)
   CISH positive 10 (18.9%)
   CISH positive in DCIS 2 (3.8%)
CK 5/6 3)  
   Triple-negative (ER-, PR-, Her-2/neu-) 11 (20.8%)
   Basal-like carcinoma (ER-, PR-, Her-2/neu-, CK5/6+) 8 (15.1%)
  1. 1,3) Cut off point used for ER and PR immunohistochemistry is 10% of positively stained tumour cell nuclei and 10% cytoplasmic staining for CK5/6.
  2. 2) All IHC Her 2+ and 3+ cases were retested by CISH. Scoring of HER2/neu immunohistochemistry: Score 0: no staining is observed or cell membrane staining is observed in less than 10% of tumour cells. Score 1+: a faint perceptible membrane staining can be detected in more than 10% of the tumour cells or cells are only stained in part of their membrane. Score 2+: a weak to moderate complete membrane staining is observed in more than 10% of the tumour cells. Score 3+: a strong complete membrane staining is observed in more than 10% of the tumour cells.